smv3 news

Novaremed Announces Completion of NIH-sponsored Phase 2b Study with Non-opioid NRD.E1 for the Treatment of Chronic Pain Associated with Diabetic Peripheral Neuropathy

We are proud to see our analytical and metabolism work appear in a recent publication of our customer Novaremed

This year the lectures took place live, were streamed and recorded. A challenge.. (in german)

We proudly report the publication of one of our biomarker success stories on Autotaxin inhibitors.

The new leadXpro website is online – check out its enormous progress in membrane protein structure biology

The work of our team at Roche has been published in a paper on selective Aldosterone Synthase compounds and even made it on the title picture of the article

Can we assess pharmacokinetics at low femtomolar levels? We face the challenge..

Outsourced early development – Managing a preclinical development with partner PKI

University of Oxford spinoff “OMass Technologies” visits Switzerland on march 16, 2018 – interested in meeting them?

Read about our work for Art exhibition “TonArt-TonWerk-DieZweite” in Lausen

smv3.ch enters Swiss Trade Register as GmbH

The University of Basel hires smv3.ch for an analytical lecture in the ‘Master of Drug Sciences’ course